A multi-centric, randomized, double blind, parallel group, active controlled, comparative Phase III clinical trial to evaluate the efficacy and safety of FDC of Bepotastine besilate 10mg/10mg + Montelukast sodium 5mg/10mg tablet versus Montelukast Sodium 5mg and Montelukast Sodium 10mg tablet in subjects diagnosed with Allergic Rhinitis.
Latest Information Update: 31 Jan 2020
At a glance
- Drugs Bepotastine besilate/montelukast (Primary) ; Montelukast
- Indications Allergic rhinitis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Windlas Biotech
Most Recent Events
- 31 Jan 2020 New trial record